Praxis Precision Medicines (PRAX) Consolidated Net Income (2019 - 2026)

Praxis Precision Medicines has reported Consolidated Net Income for 8 years, with the latest figure at -$105.9 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income fell 41.66% year-over-year to -$105.9 million; the trailing twelve-month figure through Mar 2026 stood at -$357.3 million (down 53.36% YoY), and the FY2025 full-year result was -$326.2 million, down 62.96% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$105.9 million, down from -$97.0 million in the prior quarter.
• The five-year high for Consolidated Net Income was -$25.5 million in Q3 2023, with the low at -$105.9 million in Q1 2026.
• Average Consolidated Net Income over 5 years is -$57.2 million, with a median of -$56.8 million recorded in 2024.
• Year-over-year, Consolidated Net Income sank 151.52% in 2022 and surged 44.67% in 2023.
• Tracing PRAX's Consolidated Net Income over 5 years: stood at -$41.5 million in 2022, then jumped by 32.92% to -$27.8 million in 2023, then slumped by 130.01% to -$64.0 million in 2024, then tumbled by 51.74% to -$97.0 million in 2025, then retreated by 9.08% to -$105.9 million in 2026.
• The last three Consolidated Net Income figures came in at -$105.9 million (Q1 2026), -$97.0 million (Q4 2025), and -$78.4 million (Q3 2025), per Business Quant data.

Peer Comparison